Centessa IPO Presentation Deck

SerpinPC: Emerging Safety Data and Ability to Reduce Bleeding PHASE 1 SAD COMPLETED Healthy Volunteers SerpinPC conc. (ng/ml) 1500- n-3, SerpinPC 0.03 mg/kg SC* SPAVALANK THE n=3, SerpinPC 0.003 mg/kg IV inf 1000- n=3, SerpinPC 0.01 mg/kg IV inf FAVORABLE PK OBSERVED 500- n-3, SerpinPC 0.003 mg/kg IV inf n=3, SerpinPC 0.001 mg/kg IV inf 200 0.6mg/kg 400 Time (hours) n=3, SerpinPC 1.2 mg/kg 5C 600 n-3, Serpin PC 0.6mg/kg SC n-3, SerpinPC 0.3 mg/kg SC* Tmax 50 hours Terminal t₁/24 -5 days n-3, Serpin PC 0.1 mg/kg SC* 800 Patients with severe hemophilia EMERGING SAFETY DATA IN PHASE 1 STUDY • No SerpinPC related adverse events • No injection site reactions • No thrombosis Apcintex • No Serpin PC-related increase in cytokines • No increase in D-dimer - including following treatment of breakthrough bleeds with factor concentrate • No ADAs REDUCED BLEEDING AFTER SINGLE INJECTION During 8 weeks following single injection of SerpinPC in 12 subjects with severe hemophilia • 55% reduction in all bleeds 72% reduction in joint & muscle bleeds . 5/12 subjects had zero spontaneous bleeds All subjects requested enrollment in Phase 2a multiple dose study CENTESSA 20

View entire presentation